Диссертация (1141037), страница 30
Текст из файла (страница 30)
298-303.141.Ozturk M., Kanbay M., Kasapoglu B. et al. «Therapeutic approach to familialMediterranean fever: a review update». Clin. Exp. Rheumatol., 2010, no. 29, pp. 77-86.142.Petrushkin H., Stanford M., Fortune F. et al. «Clinical Review: Familial MediterraneanFever—An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment».Ocular Immunology & Inflammation, Early Online, 2015, рр.1–9.143.Pope R.M., Tschopp J. «The role of interleukin-1 and the inflammasome in gout:implications for therapy».
Arthritis Rheum., 2007, no. 56, pp. 3183-3188144.Portincasa P. «Colchicine, Biologic Agents and More for the Treatment of FamilialMediterranean Fever. The Old, the New, and the Rare». Current Medicinal Chemistry,2016, no. 23, pp. 60-86.145.Pras M. «What is familial Mediterranean fever?». Familial Mediterranean fever: IIInternational Conference on FMF. -Antalya, 2000. P.8-12.146.Rees F.; Hui M.; Doherty M. «Optimizing current treatment of gout». Nat. Rev.Rheumatol., 2014, no. 10, pp. 271-283.147.Reimann HA. «Periodic disease». JAMA 1948, no. 136, pp. 239-244.148.Repa A., Bertsias G. K, Petraki E.
et al. «Dysregulated production of interleukin-1bupon activation of the NLRP3 inflammasome in patients with familial Mediterraneanfever». Human Immunology 2015, no. 76, pp.488–495.149.Roberge C.J.,Gaudry M., Gilbert C. et al. «Paradoxical effects of colchicine on theactivation of human neutrophilis by chemotactic factors and inflammatory microcrystal».J. Leukocl Biol., 1996, no.
59, pp. 864-871.150.Rozenbaum M, Boulman N, Feld J, et al. «Intravenous colchicine treatment for sixmonths: adjunctive therapy in familial Mediterranean fever (FMF) unresponsive to oralcolchicines». Clin Exp Rheumatol, 2009, no. 27 (Suppl. 53), p.105.181151.Said R., Hamzeh Y., Musleh T. et al. «Rapid progressive glomerulonephritis inpatients with FMF». Am. J. of Kidney Disease, 1989, v. 14, 5, pр. 412-416.152.Seyahi E., Ozdogan H., Celik S. et al. «Treatment options in colchicine resistantfamilial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents».Clin. Exp.
Rheumatol., 2006, no. 24, pp. 99-103.153.Siegal S. «Benign paroxysmal peritonitis». Ann Intern Med 1945, no. 23, pp. 1-21.154.Simon A., van der Meer J.W.S. «Pathogenesis of familial periodic fever syndromes orhereditary inflammatory syndromes». Am J Physiol Regul Integr Comp Physiol 2007, no.292, pp. 86–98.155.Sohar E, Gafni J, Pras M, Heller H. «Familial Mediterranean fever. A survey of 470cases and review of the literature». Am J Med, 1967, no.
43, pp. 227-53.156.Sozeri B., Kasapcopur O. «Biological Agents in Familial Mediterranean FeverFocusing on Colchicine Resistance and Amyloidosis». Current Medicinal Chemistry,2015, no. 22, pp. 1986-1991.157.Stoffels, M.; Szperl, A.; Simon, A. et al. «MEFV mutations affecting pyrin amino acid577 cause autosomal dominant autoinflammatory disease». Ann. Rheum. Dis., 2014, no.73, pp. 455-461.158.Taylan A., Gurler O., Toprak B. et al. «S1000A12, Chitotriosidase, and Resolvin D1as Potential Biomarkers of Familial Mediterranean Fever».
Jkms. 2015, no. 30, pp.12411245.159.Ter Haar N.M.; Frenkel J. «Treatment of hereditary autoinflammatory diseases». Curr.Opin. Rheumatol., 2014, no. 26, pp. 252-258.160.Ter Haar N., Lachmann H., Ozen S. et al. «Treatment of autoinflammatory diseases:results from the Eurofever Registry and a literature review». Ann.
Rheum. Dis., 2013, no.72, pp. 678-685.161.Terkeltaub R.A. «Colchicine update: 2008». Semin Arthritis Rheum., 2009, no. 38, pp.411-419.162.Terzi M., Taskın E., Akdemir N. U. et al. «The relationship between familialMediterranean fever gene (MEFV) mutations and clinical and radiologic parameters inmultiple sclerosis patients». International Journal of Neuroscience, 2015; Vol.125(2),pp.116–122182163.Touitou I., Milhavet F., Cuisset L.
et al. «Response to Li and Zhang: infevers, a humangene mutation database for autoinflammatory diseases including disseminated superficialactinic porokeratosis». J. Dermatol. Sci., 2014, no. 75, pp. 208-209.164.Tufan A., Babaoglu M.O., Akdogan A. et al. «Association of drug transporter geneABCB1 (MDR1) 3435C to T polymorphism with colchicines response in familialMediterranean fever». J. Rheumatol., 2007, no. 34, pp. 1540-1544.165.Tunca M.; Akar S.; Soyturk M.
et al. «The effect of interferon alpha administration onacute attacks of familial Mediterranean fever: A doubleblind, placebo-controlled trial».Clin. Exp. Rheumatol., 2004, no. 22, pp. 37-40166.Tunca M.; Tankurt E.; Akbaylar Akpinar H. et al. «The efficacy of interferon alpha oncolchicine-resistant familial Mediterranean fever attacks: a pilot study».
Br. J. Rheumatol.,1997, no. 36, pp. 1005-1008.167.Tweezer-Zaks N.; Rabinovich E.; Lidar M.; Livneh A. «Interferon-alpha as atreatment modality for colchicine- resistant familial Mediterranean fever». J. Rheumatol.,2008, no. 35, pp. 1362-1365.168.Weinert C., Grutter C. et al. «The crystal structure of human pyrin b30.2 domain:implication for mutations associated with familial mediterranean fever».
J. Mol. Biol.2009, no. 394, pp. 226−236.169.Wu B, Xu T, Li Y et al. «Interventions for reducing inflammation in familialMediterranean fever (Review)». The Cochrane Collaboration, 2015, pp. 10-12, 15-17, 2223.170.Yesilkaya S., Acikel C., Fidanci B.E. et al. «Development of a medication adherencescale for familial Mediterranean fever (MASIF) in a cohort of Turkish children». Clin ExpRheumatol, 2015, no. 33 (Suppl. 94), pp.156-162.171.Yalсinkaya S., Ozen S., Ozcakar Z.B. et al. «A new set of criteria for the diagnosis offamilial Mediterranean fever in childhood». Rheumatology 2009, no. 48, pp. 395-8.172.Yoldaş T.
C. , Cakar N., Başaran O. «The effect of colchicine and disease severityon physical growth in children with familial Mediterranean fever». Clin Rheumatol. 2015,DOI 10.1007/s10067-015-3077-9173.Zemer D.; Revach M.; Pras M. et al. «A controlled trial of colchicine inpreventingattacks of familial Mediterranean fever». N. Engl.
J. Med., 1974, no. 291,pp.932-934.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
